Trial Profile
Conditioning With Cyclophosphamide, Fludarabine and Antithymocyte Globulin for Allogeneic Hematopoietic Cell Transplantation in Lower Risk Myelodysplastic Syndrome
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
- Indications Graft-versus-host disease; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms CyFluATG
- 14 Dec 2010 New trial record